1003 related articles for article (PubMed ID: 26747759)
1. High content analysis platform for optimization of lipid mediated CRISPR-Cas9 delivery strategies in human cells.
Steyer B; Carlson-Stevermer J; Angenent-Mari N; Khalil A; Harkness T; Saha K
Acta Biomater; 2016 Apr; 34():143-158. PubMed ID: 26747759
[TBL] [Abstract][Full Text] [Related]
2. Minimal 2'-O-methyl phosphorothioate linkage modification pattern of synthetic guide RNAs for increased stability and efficient CRISPR-Cas9 gene editing avoiding cellular toxicity.
Basila M; Kelley ML; Smith AVB
PLoS One; 2017; 12(11):e0188593. PubMed ID: 29176845
[TBL] [Abstract][Full Text] [Related]
3. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
4. Scaffold-mediated non-viral delivery platform for CRISPR/Cas9-based genome editing.
Chin JS; Chooi WH; Wang H; Ong W; Leong KW; Chew SY
Acta Biomater; 2019 May; 90():60-70. PubMed ID: 30978509
[TBL] [Abstract][Full Text] [Related]
5. Non-Viral CRISPR/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic Nanoparticle Co-Delivery of Cas9 mRNA and sgRNA.
Miller JB; Zhang S; Kos P; Xiong H; Zhou K; Perelman SS; Zhu H; Siegwart DJ
Angew Chem Int Ed Engl; 2017 Jan; 56(4):1059-1063. PubMed ID: 27981708
[TBL] [Abstract][Full Text] [Related]
6. A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing.
Finn JD; Smith AR; Patel MC; Shaw L; Youniss MR; van Heteren J; Dirstine T; Ciullo C; Lescarbeau R; Seitzer J; Shah RR; Shah A; Ling D; Growe J; Pink M; Rohde E; Wood KM; Salomon WE; Harrington WF; Dombrowski C; Strapps WR; Chang Y; Morrissey DV
Cell Rep; 2018 Feb; 22(9):2227-2235. PubMed ID: 29490262
[TBL] [Abstract][Full Text] [Related]
7. Fast and Efficient CRISPR/Cas9 Genome Editing In Vivo Enabled by Bioreducible Lipid and Messenger RNA Nanoparticles.
Liu J; Chang J; Jiang Y; Meng X; Sun T; Mao L; Xu Q; Wang M
Adv Mater; 2019 Aug; 31(33):e1902575. PubMed ID: 31215123
[TBL] [Abstract][Full Text] [Related]
8. Gene editing and clonal isolation of human induced pluripotent stem cells using CRISPR/Cas9.
Yumlu S; Stumm J; Bashir S; Dreyer AK; Lisowski P; Danner E; Kühn R
Methods; 2017 May; 121-122():29-44. PubMed ID: 28522326
[TBL] [Abstract][Full Text] [Related]
9. Development of ionizable lipid nanoparticles and a lyophilized formulation for potent CRISPR-Cas9 delivery and genome editing.
Sun Q; Zhang H; Ding F; Gao X; Zhu Z; Yang C
Int J Pharm; 2024 Mar; 652():123845. PubMed ID: 38266942
[TBL] [Abstract][Full Text] [Related]
10. Postnatal Cardiac Gene Editing Using CRISPR/Cas9 With AAV9-Mediated Delivery of Short Guide RNAs Results in Mosaic Gene Disruption.
Johansen AK; Molenaar B; Versteeg D; Leitoguinho AR; Demkes C; Spanjaard B; de Ruiter H; Akbari Moqadam F; Kooijman L; Zentilin L; Giacca M; van Rooij E
Circ Res; 2017 Oct; 121(10):1168-1181. PubMed ID: 28851809
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of lipid Nanoparticle-Mediated delivery of CRISPR-Cas9 RNP versus mRNA/sgRNA for gene editing in vitro and in vivo.
Walther J; Porenta D; Wilbie D; Seinen C; Benne N; Yang Q; de Jong OG; Lei Z; Mastrobattista E
Eur J Pharm Biopharm; 2024 Mar; 196():114207. PubMed ID: 38325664
[TBL] [Abstract][Full Text] [Related]
12. Non-viral and viral delivery systems for CRISPR-Cas9 technology in the biomedical field.
He ZY; Men K; Qin Z; Yang Y; Xu T; Wei YQ
Sci China Life Sci; 2017 May; 60(5):458-467. PubMed ID: 28527117
[TBL] [Abstract][Full Text] [Related]
13. On Improving CRISPR for Editing Plant Genes: Ribozyme-Mediated Guide RNA Production and Fluorescence-Based Technology for Isolating Transgene-Free Mutants Generated by CRISPR.
He Y; Wang R; Dai X; Zhao Y
Prog Mol Biol Transl Sci; 2017; 149():151-166. PubMed ID: 28712495
[TBL] [Abstract][Full Text] [Related]
14. Cholesterol-rich lipid-mediated nanoparticles boost of transfection efficiency, utilized for gene editing by CRISPR-Cas9.
Hosseini ES; Nikkhah M; Hosseinkhani S
Int J Nanomedicine; 2019; 14():4353-4366. PubMed ID: 31354265
[No Abstract] [Full Text] [Related]
15. CRISPR/Cas9 gene-editing strategies in cardiovascular cells.
Vermersch E; Jouve C; Hulot JS
Cardiovasc Res; 2020 Apr; 116(5):894-907. PubMed ID: 31584620
[TBL] [Abstract][Full Text] [Related]
16. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
[TBL] [Abstract][Full Text] [Related]
17. Potential pitfalls of CRISPR/Cas9-mediated genome editing.
Peng R; Lin G; Li J
FEBS J; 2016 Apr; 283(7):1218-31. PubMed ID: 26535798
[TBL] [Abstract][Full Text] [Related]
18. A CRISPR/Cas9 guidance RNA screen platform for HIV provirus disruption and HIV/AIDS gene therapy in astrocytes.
Huang Z; Nair M
Sci Rep; 2017 Jul; 7(1):5955. PubMed ID: 28729655
[TBL] [Abstract][Full Text] [Related]
19. Cell-Selective Messenger RNA Delivery and CRISPR/Cas9 Genome Editing by Modulating the Interface of Phenylboronic Acid-Derived Lipid Nanoparticles and Cellular Surface Sialic Acid.
Tang Q; Liu J; Jiang Y; Zhang M; Mao L; Wang M
ACS Appl Mater Interfaces; 2019 Dec; 11(50):46585-46590. PubMed ID: 31763806
[TBL] [Abstract][Full Text] [Related]
20. Design and Evaluation of Guide RNA Transcripts with a 3'-Terminal HDV Ribozyme to Enhance CRISPR-Based Gene Inactivation.
Berkhout B; Gao Z; Herrera-Carrillo E
Methods Mol Biol; 2021; 2167():205-224. PubMed ID: 32712922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
